Diabetes
Refine Search
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Pharmaceutical
Danish diabetes care giant Novo Nordisk (NOV: N) plans to meet the entire demand of Russia for insulin over next few years, according to Kenneth Mortensen, vice president of Novo Nordisk, who is the director of the Russian factory in Kaluga. 2 May 2016
Pharmaceutical
Danish diabetes giant Novo Nordisk has announced positive top-line results from a Phase III trial of semaglutide in patients with type 2 diabetes 29 April 2016
Pharmaceutical
Danish diabetes care giant Novo Nordisk reported strong first-quarter 2016 revenue growth this morning, with sales up 8% (+9% local currencies) at 27.2 billion Danish kroner ($4.12 billion). 29 April 2016
Pharmaceutical
Eli Lilly has reported first-quarter 2016 financial results, with earnings missing expectations, though sales were better than analysts’ forecasts. 26 April 2016
Pharmaceutical
Danish diabetes giant Novo Nordisk is to invest more than 100 million euros ($112.5 million) in production facilities at its site in northern France. 25 April 2016
Generics
Lannett plans to co-develop a generic insulin pharmaceutical product for the US market with its strategic partner in China, YiChang HEC ChangJiang Pharmaceutical Co. 23 April 2016
Pharmaceutical
While Boehringer Ingelheim is still enjoying very strong sales of its chronic obstructive pulmonary disease drug Spiriva (tiotropium), the German privately-owned major is looking at diabetes as its next long-term growth driver. 20 April 2016
Pharmaceutical
Canada’s Transition Therapeutics says it has received notification that US pharma major Eli Lilly will not elect to advance diabetes drug candidate, TT401 into Phase III development. 19 April 2016
Pharmaceutical
Germany’s Boehringer Ingelheim and US pharma major Eli Lilly said today they plan to conduct two outcome trials investigating the diabetes medicine Jardiance (empagliflozin) for the treatment of people with chronic heart failure. 19 April 2016
Pharmaceutical
In April, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) started a new safety review and extended the scope of an ongoing review procedure. 15 April 2016
Pharmaceutical
Responding to mounting evidence, the US Food and Drug Administration said on Friday it is requiring labeling changes regarding the recommendations for metformin-containing medicines for diabetes to expand metformin’s use in certain patients with reduced kidney function. 9 April 2016
Pharmaceutical
A number of barriers are impeding access to insulin around the world, according to new research published today by Health Action International, Geneva University Hospitals/University of Geneva and Boston University School of Public Health. 7 April 2016
Pharmaceutical
Privately-held Servier has marked 40 years of operations in Brazil by announcing plans to launch 15 new meds not only for diabetes, but also for cancer and cardiovascular diseases – the country’s second biggest killers. 7 April 2016
Pharmaceutical
A US Food and Drug Administration safety review has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. 6 April 2016
Pharmaceutical
Data from a three-year trial of Novo Nordisk’s obesity drug Saxenda (liraglutide injection) have shown positive results. 5 April 2016
Pharmaceutical
Novo Nordisk presented new results from two clinical trials investigating the efficacy and safety of GLP-1 receptor agonists, semaglutide and already blockbuster drug Victoza (liraglutide) for the treatment of type 2 diabetes at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, USA, on April 2. 3 April 2016
Pharmaceutical
As work started on its new $1.8 billion diabetes medicine production facility in Clayton, North Carolina, Project Director Gary Lohr spoke about the significance of the huge investment for Novo Nordisk. 30 March 2016
Biosimilars
Biocon says that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved its biosimilar insulin glargine. 29 March 2016
Pharmaceutical
Indian drug major Sun Pharma and the Indian subsidiary of Anglo-Swedish pharma firm AstraZeneca have announced a partnership for the distribution of dapagliflozin, an innovative type 2 diabetes medicine, in India. 24 March 2016
Pharmaceutical
Janssen Research & Development said today that it has entered into two new research agreements established through its Disease Interception Accelerator (DIA), a research unit focused on the prediction and preemption of diseases. 22 March 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze